

SCIENTIFIC REPORTS

OPEN

Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid- β

Received: 27 October 2015
Accepted: 13 January 2016
Published: 11 February 2016

Giuseppe Di Fede¹, Marcella Catania¹, Emanuela Maderna¹, Michela Morbin¹, Fabio Moda¹, Laura Colombo³, Alessandro Rossi³, Alfredo Cagnotto³, Tommaso Virgilio¹, Luisa Palamara¹, Margherita Ruggerone¹, Giorgio Giaccone¹, Ilaria Campagnani¹, Massimo Costanza², Rosetta Pedotti², Matteo Salvalaglio⁴, Mario Salmona³ & Fabrizio Tagliavini¹

We developed a novel therapeutic strategy for Alzheimer's disease (AD) exploiting the properties of a natural variant of Amyloid- β (A β) carrying the A2V substitution, which protects heterozygous carriers from AD by its ability to interact with wild-type A β , hindering conformational changes and assembly thereof. As prototypic compound we designed a six-mer mutated peptide (A β 1-6_{A2V}), linked to the HIV-related TAT protein, which is widely used for brain delivery and cell membrane penetration of drugs. The resulting molecule [A β 1-6_{A2V}TAT(D)] revealed strong anti-amyloidogenic effects *in vitro* and protected human neuroblastoma cells from A β toxicity. Preclinical studies in AD mouse models showed that short-term treatment with A β 1-6_{A2V}TAT(D) inhibits A β aggregation and cerebral amyloid deposition, but a long treatment schedule unexpectedly increases amyloid burden, although preventing cognitive deterioration. Our data support the view that the A β _{A2V}-based strategy can be successfully used for the development of treatments for AD, as suggested by the natural protection against the disease in human A2V heterozygous carriers. The undesirable outcome of the prolonged treatment with A β 1-6_{A2V}TAT(D) was likely due to the TAT intrinsic attitude to increase A β production, avidly bind amyloid and boost its seeding activity, warning against the use of the TAT carrier in the design of AD therapeutics.

Alzheimer's disease (AD) is the most common form of dementia in the elderly. Its clinical course is slow but irreversible since no disease-modifying treatments are currently available. As a result, this illness has a huge socio-sanitary impact and designing of effective therapies is considered a public health priority.

A central pathological feature of AD is the accumulation of misfolded Amyloid-beta (A β) peptides in the form of oligomers and amyloid fibrils in the brain¹⁻³. It has been advanced that aggregated A β species, particularly oligomeric assemblies, trigger a cascade of events that lead to hyperphosphorylation, misfolding and assembly of the tau protein with formation of neurofibrillary tangles and disruption of the neuronal cytoskeleton, widespread synaptic loss and neurodegeneration. According to this view, altered A β species are the primary cause of AD and the primary target for therapeutic intervention^{3,4}.

A β peptides derive from proteolytic processing of a large (695/770 amino acids) type 1 transmembrane glycoprotein known as amyloid beta precursor protein (APP). APP is cleaved at the N-terminus of the A β domain by β -secretase, forming a large, soluble ectodomain (sAPP β) and a 99-residue, membrane-retained C-terminal fragment (C99). Subsequently, γ -secretase cleaves C99 to release A β with different carboxyl termini, including A β 40, A β 42 and other minor species⁵. APP may undergo an alternative, non-amyloidogenic processing where the protein is cleaved within the A β domain by α -secretase, forming a soluble ectodomain (sAPP α) and an 83-residue C-terminal fragment (C83)^{5,6}.

We identified a novel mutation in the APP gene resulting in A-to-V substitution at codon 673, corresponding to position 2 in the A β sequence⁷. Studies on biological samples from an A673V homozygous carrier, and cellular

¹Neurology V and Neuropathology Unit, IRCCS Foundation "Carlo Besta" Neurological Institute (INCB), Via Celoria 11, 20133 Milan, Italy. ²Neuroimmunology and Neuromuscular Disorder Unit, IRCCS Foundation "C. Besta" Neurological Institute (INCB), Via Celoria 11, 20133 Milan, Italy. ³Department of Molecular Biochemistry and Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Via La Masa 19, 20158 Milan, Italy. ⁴Department of Chemical Engineering, University College London, London WC1E 7JE, UK. Correspondence and requests for materials should be addressed to G.D.F. (email: gdifede@istituto-besta.it)




Figure 1. Analysis of 1.5 μs explicit solvent MD simulations of the $A\beta 1-6_{WT}$ and $A\beta 1-6_{A2V}$ peptides. (A) Apolar character of the peptide SAS represented as the ratio between SAS_{apolar} and the total SAS. (B) Gyration radius distribution. (C) Analysis of secondary structure propensity. "Structure" indicates residues possessing a defined secondary structure, in this case structure indicates residues in a "turn" configuration. "Coil" indicates residues that do not display a defined secondary structure. Analysis of the secondary structure was carried out with DSSP. (D) Typical compact "turn" and elongated "coil" configurations reported for the $A\beta 1-6_{A2V}$ and $A\beta 1-6_{WT}$, respectively. (E) Analysis of the most populated structural clusters. Representative structures of the six most probable clusters were reported. The coil configuration has been highlighted in green, the turn in red and a partly folded turn in orange.




Figure 2. Analysis of the effects of Aβ1-6_{WT}(D), Aβ1-6_{A2V}(D) and Aβ1-6_{A2V}TAT(D) on neurotoxicity in cell models. SH-SY5Y cells were differentiated with 10μM retinoic acid. After 6 days the proper peptide was added to culture medium and cell viability was assessed after 24 h by MTT test. (A,B) Neither Aβ1-6_{WT}(D) nor Aβ1-6_{A2V}(D) are significantly toxic when added to culture medium of differentiated SH-SY5Y cells. Conversely, Aβ1-42_{WT} reduces cell viability by 35%. * Significance vs non-treated cells. (C,D) Both Aβ1-6_{WT}(D) and Aβ1-6_{A2V}(D) are able to counteract the toxic effect of Aβ1-42_{WT}. Aβ1-6_{A2V}(D) showed a stronger effect than Aβ1-6_{WT}(D). (E) Aβ1-6_{A2V}TAT(D) is not toxic when added to culture medium at concentrations ranging between 1 and 5μM, while it reduces cell viability at higher concentrations. * Significance vs non-treated cells. (F) Aβ1-6_{A2V}TAT(D) showed a dose-dependent effect in reducing Aβ1-42_{WT} toxicity. Comparison of cell viability was performed by Student t-test.




Figure 3. Inhibition of aggregation of Aβ1-42_{WT} by Aβ1-6_{A2V} TAT(D). Polarized-light (A,B), electron microscopy (C,D) and atomic force microscopy (AFM) (E–H) studies showing the inhibitory effects of Aβ1-6_{A2V} TAT(D) on amyloid formation, fibril production and oligomerization by Aβ1-42_{WT}. In polarized-light and EM studies, both peptides were used at 0.125 mM, molar ratio = 1:1 or 1:4 respectively, with 20 days incubation. From 5–20 days, 1:1 co-incubation of the two peptides (B,D) displayed a lower amyloid fibril content respect to Aβ1-42_{WT} alone (A,C), showing protofibrils, short fibrils and disaggregated granular

material. **E,F**: Representative Tapping mode of AFM images as determined by amplitude error data of A β 1-42_{WT} oligomers. A β 1-42_{WT} peptide 100 μ M in phosphate buffer 50 mM, pH 7.4 was incubated at 4 °C for 24 h alone (**E**) (Z range: -10/ + 10 mV) or in presence of A β 1-6_{A2V} TAT(D) (**F**) (Z range: -10/ + 25 mV). The molar ratio of A β 1-42_{WT} to A β 1-6_{A2V}TAT(D) was 1:4. Scale bar: 1 μ m, inset: 200 nm. (**G,H**): height plot profiles obtained along different lines traced on the topographic AFM images. Overall, these effects were already evident in the 1:1 mixture of the two peptides (data not shown), suggesting that the inhibition of A β 1-42_{WT} aggregation by A β 1-6_{A2V}TAT(D) is a dose-dependent effect.

and *C. elegans* models indicated that this mutation shifts APP processing towards the amyloidogenic pathway with increased production of amyloidogenic peptides. Furthermore, the A2V substitution in the A β sequence (A β _{A2V}) increases the propensity of the full-length peptides (i.e., A β 1-40 and A β 1-42) to adopt a β -sheet structure, boosts the formation of oligomers both *in vitro* and *in vivo* and enhances their neurotoxicity⁸⁻¹⁰. Following the observation that humans carrying the mutation in the heterozygous state do not develop AD, we carried out *in vitro* studies with synthetic peptides that revealed the extraordinary ability of A β _{A2V} to interact with wild-type A β (A β _{WT}), interfering with its nucleation or nucleation-dependent polymerization⁷. This provides grounds for developing a disease-modifying therapy for AD based on modified A β _{A2V} peptides retaining the key functional properties of parental full-length A β _{A2V}.

Following this approach, we generated a mutated six-mer peptide (A β 1-6_{A2V}), constructed entirely by D-amino acids [A β 1-6_{A2V}(D)] to increase its stability *in vivo*, whose interaction with full-length A β _{WT} hinders oligomer production and prevents amyloid fibril formation⁸.

These results prompted us to develop a prototypic compound by linking A β 1-6_{A2V}(D) to an all-D form of TAT sequence [TAT(D)], a peptide derived from HIV that powerfully increases virus transmission to neighbour cells¹¹, and is widely used for brain delivery of drugs¹²⁻¹⁴. Here we report that this compound [A β 1-6_{A2V} TAT(D)] has strong anti-amyloidogenic effects *in vitro*, leading to inhibition of oligomer, amyloid fibril formation and of A β -dependent neurotoxicity. Preclinical studies showed that a short-term treatment with this peptide in an AD mouse model prevents A β aggregation and amyloid deposition in the brain but longer treatment unexpectedly increases amyloid burden, most likely due to the TAT intrinsic attitude to enhance A β production and to avidly bind amyloid and boost its seeding activity, warning against the use of this carrier in therapeutic approaches for AD.

Results

In silico molecular modeling of A β _{A2V} peptide variants. To predict the structural basis of the anti-amyloidogenic effect of A β 1-6_{A2V}(D), a comparative conformation analysis of WT and mutated A β 1-6 was carried out with all-atom classical MD simulations in explicit solvent. Both A β 1-6_{WT} and A β 1-6_{A2V} are intrinsically disordered peptides characterized by high flexibility. Nevertheless, the substitution of Ala2 with a Val residue induces significant changes in the appearance of the peptide in solution, resulting in an increase of the apolar character of the solvent accessible surface (SAS) (Fig. 1A) and in a modification of the gyration radius distribution in the A β 1-6_{A2V}. Figure 1B shows that the probability distribution of the gyration radius is characterized by a global shift to smaller values and by the appearance of a shoulder in the distribution corresponding to gyration radii of 0.5 nm.

An analysis of the secondary structure content displayed by the peptides (Fig. 1C) shows that, while both A β 1-6_{A2V} and A β 1-6_{WT} display a predominant coil configuration, A β 1-6_{A2V} shows a slightly higher propensity to form secondary structure motifs involving two to three residues. A β 1-6_{A2V} in fact displays a propensity to form a turn involving the Glu3, Phe4 and Arg5 residues (Fig. 1D). The most populated structural clusters¹⁵ (Fig. 1E), in A β 1-6_{WT} are characterized by an elongated coil structure accounting for 52.6% of the configurations, while the compact “turn” state is only the third most probable cluster, with a population of around 9%. Conversely, in the A β 1-6_{A2V}, while the most populated structure is still an elongated coil (32%), the “turn” configuration is the second most populated structural cluster (31%).

Both A β 1-6_{WT} and A β 1-6_{A2V} under physiological conditions are characterized by intramolecular salt bridges such as those between Asp1 and Arg5 or Glu3-Arg5. In the extended coil configuration (Fig. 1E), salt bridges can be dynamically formed and dissociated without requiring a specific rearrangement of the peptide backbone. However, in the turn configuration salt bridges are typically dissociated; the interaction of the apolar Val2 sidechain with the Arg5 sidechain stabilizes such a dissociated state. The additional sterical hindrance to the rearrangement induced by the Val2 sidechain also contributes to the stabilization of the turn configuration of the A2V peptide.

The propensity of the A2V mutant to adopt a Glu3-Arg5 turn configuration characterized by a significant lifetime can be interpreted as the probable source of the heterotypic interaction of the A β 1-6_{A2V} with full-length A β , which results in hindering its assembly.

A β 1-6_{A2V} retains the *in vitro* anti-amyloidogenic features of the parental full-length peptide. We previously showed that A β 1-6_{A2V}(D) destabilizes the secondary structure of A β 1-42_{WT}⁸ and is even more effective than the WT peptide [A β 1-6_{WT}(D)] and the A2V-mutated L-isomer [A β 1-6_{A2V}(L)] at preventing the aggregation of full-length A β _{WT}⁸.

Treatment of SH-SY5Y cells with A β 1-6_{WT}(D) or A β 1-6_{A2V}(D) showed that neither is toxic for living cells even at high concentrations (20 μ M) (Fig. 2A,B) and that both peptides are able to reduce the toxicity induced by A β 1-42_{WT} (Fig. 2C,D). However, A β 1-6_{A2V}(D) showed a stronger effect in counteracting the reduction of cell viability caused by A β 1-42_{WT} (Fig. 2D), suggesting that the A-to-V substitution actually amplifies the protective effects of the six-mer peptide.




Figure 4. *In vivo* anti-amyloidogenic effects of treatment with A β 1-6_{A2V} TAT(D) – pilot study in huAPP^{Swe}/moAPP^{0/0} mice. (A): Effects of A β 1-6_{A2V} TAT(D) treatment on brain levels of full-length A β and A β aggregates in huAPP^{Swe}/moAPP^{0/0} mice. Mice treated i.p. with A β 1-6_{A2V} TAT(D) daily for 21 days showed a reduction of A β 40 levels in the soluble fraction, together with a decrease in aggregated A β . A β 42 in the soluble fraction and A β 40, A β 42 and aggregated A β in the insoluble fraction were not significantly lower, even though we observed a trend of reduction of these species in mice treated with A β 1-6_{A2V} TAT(D) as compared to animals treated with saline solution. Student t-test was used to compare results obtained by ELISA tests. (B,C) Prevention of *in vivo* amyloid formation in huAPP^{Swe}/moAPP^{0/0} mice by short-term treatment with A β 1-6_{A2V} TAT(D). (B) Amyloid deposits in mice treated with A β 1-6_{A2V} TAT(D) vs mice treated with saline solution (control group). Immunohistochemistry with 4G8 antibody, original magnification 4 \times . (C) Quantification of amyloid burden by ‘plaque count’ in the two experimental groups: saline treated animals (blue columns) and A β 1-6_{A2V} TAT(D)-treated mice (red columns). Evidence of reduction of amyloid burden in the group treated with A β 1-6_{A2V} TAT(D). Significance of the results was calculated by Mann-Whitney U test. Statistical differences were considered significant if $p < 0.05$.

A β 1-6_{A2V}TAT(D) maintains the *in vitro* anti-amyloidogenic properties of A β 1-6_{A2V}(D). A β 1-6_{A2V}(D) alone does not efficiently cross either the blood brain barrier (BBB) or cell membranes (data not shown). This is an important feature that would deeply limit its use as an *in vivo* anti-amyloidogenic drug. So, we linked this peptide to the all-D TAT sequence to improve the translocation of A β 1-6_{A2V}(D) across the BBB and cell membranes, minimize the degradation of the peptide and reduce the immune response elicited by the molecule. The resulting compound [A β 1-6_{A2V}TAT(D)] destabilizes the secondary structure of A β 1-42_{WT}. Indeed, CD spectroscopy studies showed that A β 1-6_{A2V}TAT(D) inhibits the acquisition of β -sheet conformation by A β 1-42_{WT} (data not shown), thus affecting the folding of the full-length peptide.

We tested the ability of A β 1-6_{A2V}TAT(D) to inhibit the fibrillogenic properties of the full-length A β *in vitro* and found that the compound hindered A β 1-42_{WT} aggregation (Fig. 3). Polarized light and electron microscopy studies on aggregates of A β 1-42_{WT} formed after 20 days incubation with or without A β 1-6_{A2V}TAT(D) revealed that the mutated peptide hinders the formation of amyloid structures (Fig. 3B) and reduces the amount of fibrils generated by the full-length peptide (Fig. 3D). Moreover, AFM analysis (Fig. 3E,H) showed that A β 1-6_{A2V}TAT(D) actually interferes with the oligomerization process of A β 1-42_{WT}. Indeed, monomeric A β 1-42_{WT}, incubated alone at a final concentration of 100 μ M, formed a family of small oligomers of different size within a range of 6–20 nm in diameter (~70%) (Fig. 3E,G). Conversely, the co-incubation with A β 1-6_{A2V}TAT(D) resulted in the formation of very small globular structures with a range of 5–8 nm in diameter and height of 200–400 pm (~70%), large and thin structures, apparently very rich in water (width: 500–700 nm; height: 200–500 pm). Notably, only rare oligomeric structures were detected (Fig. 3E,H).

These effects were observed by incubating A β 1-42_{WT} and A β 1-6_{A2V}TAT(D) at a 1:4 molar ratio, but they were also evident at equimolar concentrations of the two peptides.

Moreover, treatment of differentiated SH-SY5Y cells with A β 1-6_{A2V}TAT(D) showed that the peptide is not toxic when administered at concentrations ranging between 1 and 5 μ M (Fig. 2E). When co-incubated with A β 1-42_{WT}, A β 1-6_{A2V}TAT(D) displayed a significant dose-dependent reduction of the toxicity induced by full-length A β (Fig. 2F).

All these findings indicated that the designed A β 1-6_{A2V}TAT(D) peptide is particularly efficient at inhibiting A β polymerization and toxicity *in vitro*, and identified it as our lead compound for the subsequent *in vivo* studies.

A β 1-6_{A2V}TAT(D) is able to cross the BBB after its intraperitoneal administration. The stability of A β 1-6_{A2V}TAT(D) and A β 1-6_{A2V}TAT(L) peptides to serum proteases was determined using MALDI-TOF. The D-peptide remained stable for 48 h, while the L-peptide was rapidly degraded in about 1 h (Supplementary Fig. 3S). To check the efficacy of TAT peptide in delivering A β 1-6_{A2V} to the brain, we measured the levels of A β 1-6_{A2V}TAT(D) in brain tissue of mice treated with the compound i.p. once a week at the dose of 10 mg/kg for five months, 1 or 24 h after the last treatment. The analysis showed that A β 1-6_{A2V}TAT(D) brain levels were 145.03 ± 38.26 pg/mg tissue (mean \pm SEM) and 62.02 ± 28.68 after 1 or 24 h, respectively (Supplementary Table 3S and Fig. 4S).

A β 1-6_{A2V}TAT(D) shows *in vivo* anti-amyloidogenic effects in the huAPP^{Swe}/moAPP^{0/0} mouse model of AD. A pilot preclinical study with A β 1-6_{A2V}TAT(D) was performed on a limited number (n = 3) of transgenic mice - APP23 mice expressing the Swedish double mutation in the human APP gene and knock-out for endogenous APP (huAPP^{Swe}/moAPP^{0/0}), chosen to avoid the interference of murine APP in the anti-amyloidogenic properties of A β 1-6_{A2V}TAT(D). These mice usually begin to develop amyloid deposits at 10 months. The animals were treated i.p. at 13 months with 0.24 mg/kg of A β 1-6_{A2V}TAT(D) once a day for 3 weeks. The treatment resulted in a reduction of A β production and aggregation (Fig. 4A) and in a decrease of intracerebral amyloid deposits (Fig. 4B,C).

A β 1-6_{A2V}TAT(D) reduces A β levels and amyloid in APP^{Swe}/PS1dE9 mice in a short treatment schedule. Ultimately, we decided to treat APP^{Swe}/PS1dE9 mice (n = 20 x group) i.p. with A β 1-6_{A2V}TAT(D). The treatment started at the age of 4 months, when the deposition of amyloid in the brain of these animals usually begins, becoming consistent by 6 months. The schedule of treatment was established based on the results of a pilot study with the same mouse model, showing that the best anti-amyloidogenic effects are obtained by treating animals i.p. once a week with 10 mg/kg peptide (data not shown).

The short-term treatment (2.5 months) of APP^{Swe}/PS1dE9 mice with A β 1-6_{A2V}TAT(D) resulted in the exciting reduction of A β production and aggregation (Fig. 5B), and prevention of amyloid deposition in the brain (Fig. 5C,D) of the group treated once a week with A β 1-6_{A2V}TAT(D). This group showed an increase of A β 1-42 in the soluble fraction and a concomitant decrease in the insoluble fraction, suggesting that the treatment induces a transfer of A β 1-42 from the insoluble to soluble compartment of brain tissue, which may reflect a disaggregation of amyloid deposits. This view is corroborated by the fact that aggregated A β was reduced in both compartments. Moreover, the decrease of aggregated A β in the soluble fraction is associated with an increase of monomeric A β 1-42 levels, suggesting that A2V-based therapy changes the dynamic equilibrium between A β aggregates and A β monomers, resulting in a reduction of the most toxic A β species (i.e., soluble A β assemblies).

The reduction of amyloid deposition involved all brain areas, including the hippocampus, and was more prominent in the frontal and entorhinal cortices and olfactory bulbs (Fig. 5D).

These findings were paralleled by a slight effect on cognitive function (Fig. 5A), as suggested by performances of mice treated with A β 1-6_{A2V}TAT(D) in the Novel Object Recognition test (NOR). The results of the study showed a trend towards cognitive impairment in the control group and an opposite tendency of mice treated with A β 1-6_{A2V}TAT(D), whose cognitive performances were no worse than at the beginning of the treatment with A β 1-6_{A2V}TAT(D). In fact, the NOR test scores showed a small, albeit not statistically significant, improvement.




Figure 5. *In vivo* anti-amyloidogenic effects of a short schedule treatment with Aβ1-6_{A2V}TAT(D). (A) Novel Object Recognition Test (NOR). Recognition/Discrimination Index at the end of treatment with Aβ1-6_{A2V}TAT(D). Animals were treated with Aβ1-6_{A2V}TAT(D) once a week for 2.5 months. Comparison with control group (treated with saline solution). The significance of the results was calculated via a Mann-Whitney U test. (B) Biochemical study on mice treated with Aβ1-6_{A2V}TAT(D) once a week for 2.5 months. Aβ levels in the brains of mice treated with Aβ1-6_{A2V}TAT(D) every 7 days for 2.5 months showed an increase of Aβ42 in the soluble fraction and a concomitant decrease in the insoluble fraction. Interestingly, aggregated Aβ was reduced in both the compartments. Aβ40 was not changed compared to controls. Statistical analysis was performed via a Student's t-test and differences were considered significant if $p < 0.05$. (C,D) Neuropathological study on mice treated with Aβ1-6_{A2V}TAT(D) once a week for 2.5 months. Amyloid deposits in mice treated

with A β 1-6_{A2V}TAT(D) vs mice treated with saline solution (control group). Immunohistochemistry with 4G8 antibody, original magnification 10 \times (C). Quantification of amyloid burden by 'plaque count' and 'area fraction' in the two experimental groups: saline treated animals (blue columns) and A β 1-6_{A2V}TAT(D)-treated mice (red columns) (D). Evidence of reduction of amyloid burden in the group treated with A β 1-6_{A2V}TAT(D). The significance of the results was calculated via a Mann-Whitney U test. Statistical differences were considered significant if $p < 0.05$.

However, the final outcome of treatment (after 5 months) was an unexpected substantial increase in amyloid burden (Fig. 6C) and attenuation of the effects on A β production (Fig. 6B), while the results of the behavioral assessment by NOR suggested preserved cognitive function in the group treated with A β 1-6_{A2V}TAT(D) compared with the saline-treated mice, as indicated by significant differences in the scores for recognition and discrimination indexes obtained for the two experimental group of mice at the end of treatment (Fig. 6A).

A β 1-6_{A2V}TAT(D) induces a shift in APP processing toward the amyloidogenic pathway in a chronic treatment. The unexpected outcome of the prolonged treatment with A β 1-6_{A2V}TAT(D) spurred us to search for the causes underlying the removal of the anti-amyloidogenic effects previously observed after 2.5 months of treatment with the test compound.

To this end, we investigated the effects of A β 1-6_{A2V}TAT(D) on APP processing and found that treatment with A β 1-6_{A2V}TAT(D) resulted in a shift of APP processing towards the amyloidogenic pathway, leading to an increased C99:C83 ratio in the brain of APP^{Swe}/PS1dE9 mice (Fig. 7A–D), which presumably paves the way for overproduction of A β . Interestingly, the effects on APP processing were detected only after prolonged treatment with A β 1-6_{A2V}TAT(D) and were not observed after short-term treatment schedules, i.e., after 3 weeks in the huAPP^{Swe}/moAPP^{0/0} or after 2.5 months in the APP^{Swe}/PS1dE9 mice.

TAT peptide alone binds amyloid vigorously. Concomitant studies performed in our labs showed that A β 1-6_{A2V}TAT(D) has a special propensity to target β -amyloid deposits (Fig. 7E–H) and that this is a specific attribute of the TAT(D) sequence.

To address this point, we prepared A β 1-6_{A2V}TAT(D), A β 1-6_{WT}TAT(D), A β 1-6_{A2V}(D) and TAT(D) peptides containing a biotinylated residue at the C-terminus (Biot-peptide) to visualize their binding to amyloid plaques. Both Biot-A β 1-6_{WT}TAT(D) and Biot-A β 1-6_{A2V}TAT(D) were unable to produce any staining in brain slices of control animals (non-transgenic mice) devoid of amyloid plaques (data not shown), but they were able to bind and therefore stain the plaques in transgenic mouse brains (Fig. 7E,F respectively). Interestingly, the biotinylated form of TAT(D) [(Biot-TAT(D))] strongly stained amyloid deposits (Fig. 7G), but no immunostaining of amyloid was detected in slices incubated with Biot-A β 1-6_{A2V}(D) (Fig. 7H).

These data suggest that the anti-amyloidogenic effects of A β 1-6_{A2V}(D) are overcome in the chronic treatment by the TAT intrinsic attitude to promote amyloidogenic APP processing, bind to amyloid and boost its seeding activity, leading to an increase of amyloid burden *in vivo*.

A β 1-6_{A2V}TAT(D) induces an immune response after peripheral administration in mice. Finally, we tested the A β 1-6_{A2V}TAT(D) immunogenic properties and found that the chronic treatment with this compound results in the production of not negligible levels of serum IgG against A β 1-6_{A2V}TAT(D) as well as against full-length A β (Fig. 8A,B). Interestingly, the treatment with A β 1-6_{A2V}TAT(D) did not induce production of IgG against A β 1-6_{A2V} peptide (Fig. 8C), while 3 out of 9 mice displayed slightly increased levels of IgG against TAT(D) (Fig. 8D). These data suggest that both A β 1-6_{A2V} and TAT(D) are not *per se* strongly immunogenic, while the combination of the two peptides might confer strong immunogenicity to A β 1-6_{A2V}TAT(D) compound that, however, did not result in any evident side effect on brain, as revealed by neuropathologic studies (data not shown).

Discussion

During the last few decades, huge efforts have been made to develop disease-modifying therapies for Alzheimer, but the results of these attempts have been frustrating. The anticipated increase of AD patients in the next few decades makes the development of efficient treatments an urgent issue¹⁶. In order to prevent the disease and radically change its irreversible course, a long series of experimental strategies against the main molecular actors of the disease (A β and tau)¹⁷ or novel therapeutic targets¹⁸ have been designed based on purely theoretical grounds¹⁹ as well as on evidence mainly deriving from preclinical observations in AD animal models²⁰. However, few strategies proved suitable for application in human clinical trials, and none proved to be really effective²¹. Our approach differs from previous strategies - mainly those involving modified A β peptides that have been found to inhibit amyloidogenesis^{19,22} - since it is based on a natural genetic variant of amyloid- β (A β _{A2V}) that occurs in humans and prevents the development of the disease when present in the heterozygous state⁷.

In this context, we carried out *in vitro* and *in vivo* studies that revealed the extraordinary ability of A β _{A2V} to interact with A β _{WT}, interfering with its aggregation⁸. These findings were a proof of concept of the validity of therapeutic strategies based on the use of A β _{A2V} variant, and prompted us to develop a new disease-modifying treatment for AD by designing a six-mer mutated D-isomer peptide [A β 1-6_{A2V}(D)] linked to the short amino acid sequence derived from the HIV TAT peptide, widely used for brain delivery, to make the translocation of A β 1-6_{A2V}(D) across the BBB feasible.

The use of TAT as a carrier for brain delivery of drugs has been employed in several experimental approaches for the treatment of AD-like pathology in mouse models^{12,13}. Recently, intraperitoneal administration of a TAT-BDNF peptide complex for 1 month was shown to improve the cognitive functions in AD rodent models²³.




Figure 6. *In vivo* anti-amyloidogenic effects of prolonged treatment with Aβ1-6_{A2V}TAT(D).

(A): Novel Object Recognition Test (NOR). Recognition/Discrimination Index at the end of treatment with Aβ1-6_{A2V}TAT(D). Animals were treated with Aβ1-6_{A2V}TAT(D) once a week for 5 months. Comparison with control group (treated with saline solution). The significance of the results was calculated using a Mann-Whitney U test. (B) Biochemical study on mice treated with Aβ1-6_{A2V}TAT(D) once a week for 5 months. Aβ levels in the brains of mice treated with Aβ1-6_{A2V}TAT(D) every 7 days for 5 months showed no significant difference compared to mice treated with saline solution. However, Aβ40, Aβ42 and aggregated Aβ levels were slightly lower in both soluble and insoluble fraction of mice treated with Aβ1-6_{A2V}TAT(D). Statistical analysis was performed via a Student's t-test and differences were considered significant if $p < 0.05$. (C) Neuropathological study on mice treated with Aβ1-6_{A2V}TAT(D) once a week for 5 months. Quantification of amyloid burden by 'plaque count' and 'area fraction' in the two experimental groups: saline-treated animals (blue columns) and Aβ1-6_{A2V}TAT(D)-treated mice (red columns). Amyloid burden was unexpectedly increased

in the group treated with A β 1-6_{A2V}TAT(D) in comparison with mice treated with saline solution (control group). The significance of the results was calculated using a Mann-Whitney U test. Statistical differences were considered significant if $p < 0.05$.

A previous study showed that, following its peripheral injection, a fluorescein-labelled version of TAT is able to cross the BBB, bind amyloid plaques and activate microglia in the cerebral cortex of APPswe/PS1DE9 transgenic mice²⁴. TAT was then conjugated with a peptide inhibitor (RI-OR2, Ac-rGffvlkGr-NH2) consisting of a retro-inverted version of A β 16–20 sequence²⁵ that was found to block the formation of A β aggregates *in vitro* and to inhibit the toxicity of A β on cultured cells²⁵. Daily i.p. injection of RI-OR2-TAT for 21 days into 10-month-old APPswe/PS1DE9 mice resulted in a reduction in A β oligomer levels and amyloid- β burden in cerebral cortex²⁴.

We followed a similar strategy and initially demonstrated that A β 1-6_{A2V}(D), with or without the TAT sequence, retains *in vitro* the anti-amyloidogenic properties of the parental full-length mutated A β , since it is effective at hindering *in vitro* the production of oligomers and fibrils, the formation of amyloid and the toxicity induced by A β 1-42_{WT} peptide on SY5H-5Y cells.

Based on these results, we then decided to test *in vivo* the anti-amyloidogenic ability of A β 1-6_{A2V}TAT(D). The compound proved stable in serum after i.p. administration in mice, able to cross the BBB and associated with an immune response that was not found to cause any brain damage.

Short-term treatment with A β 1-6_{A2V}TAT(D) in the APPswe/PS1DE9 mouse model prevented cognitive deterioration, A β aggregation and amyloid deposition in brain. Unexpectedly, a longer treatment schedule, while retaining the results for cognitive impairment, attenuated the effects on A β production and increased amyloid burden, most likely due to the intrinsic amyloidogenic properties of TAT.

Indeed, we found that TAT(D), unlike A β 1-6_{A2V}(D), has a strong ability to bind amyloid deposits. This avidity for amyloid could boost the intrinsic seeding activity of amyloid plaques via a continuous and self-sustained recruitment of A β aggregates, leading to an exacerbation of the amyloidogenesis.

A similar effect of TAT was described in a study²⁶ reporting that HIV TAT promotes AD-like pathology in an AD mouse model co-expressing human APP bearing the Swedish mutation and TAT peptide (PSAPP/TAT mice). These mice indeed showed more A β deposition, neurodegeneration, neuronal apoptotic signalling, and phospho-tau production than PSAPP mice.

Moreover, TAT was found to increase A β levels by inhibiting neprilysin²⁷ or enhancing β -secretase cleavage of APP, resulting in increased levels of the C99 APP fragment and 5.5-fold higher levels of A β 42²⁸. The same study reported that stereotaxic injection of a lentiviral TAT expression construct into the hippocampus of APP/presenilin-1 (PS1) transgenic mice resulted in increased TAT-mediated production of A β *in vivo* as well as an increase in the number and size of A β plaques. This is consistent with our findings, indicating a shift in APP processing towards the amyloidogenic processing *in vivo* at the end of the 5-month treatment with A β 1-6_{A2V}TAT(D) that was not observed in shorter treatment schedules with the same compound.

Therefore, these data suggest that the final outcome of our *in vivo* studies with A β 1-6_{A2V}TAT(D) is the result of side effects of the TAT carrier, whose amyloidogenic intrinsic activity neutralized the anti-amyloidogenic properties of the A β _{A2V} variant. Nevertheless, we believe that the approach based on the use of A β _{A2V} variant can be successfully used in treating AD, because of its potential ability to tackle the main pathogenic events involved in the disease, as suggested by the natural protection against the disease which occurs in human heterozygous A673V carriers.

Interestingly, recent studies produced evidence in favour of a natural protection against AD in human carriers of the A2T A β mutation²⁹, another human A β variant characterized by an alanine-to-threonine substitution at the same APP codon of the A2V-A β mutation (APP-A673T or A β _{A2T} variant). This mutation segregates almost exclusively with individuals who never showed any sign of dementia, suggesting a possible protective role against AD in the Icelandic and Finnish populations³⁰. Additional studies tried to clarify the molecular basis of the A2T-induced protection for AD, suggesting a likely composite mechanism including effects on APP processing (with consequent decrease of A β production), and on A β structure, aggregation and neurotoxicity^{31–33}.

More recent papers reported that the A673T variant is extremely rare in other cohorts from the US and Asia and does not play a substantial role in risk for AD outside of Icelandic and Scandinavian geographic areas^{34,35}. However, the discovery of protective genetic variants like A β _{A2V} and A β _{A2T}, although rare, should prompt a novel vision of genetic studies, which until now has been limited to the identification of pathogenic variants, expanding the genetic research into the detection of “protective” DNA variations as a useful foundation for the design of efficient disease-modifying treatments in medicine.

Finally, we would emphasize that, regardless its optimal BBB delivery abilities and cell penetrating activity³⁶, some intrinsic properties of TAT sequence can promote amyloidogenesis in long treatment schedules and should be carefully taken into account whenever this peptide is employed in the design of therapeutic strategies for neurological diseases^{37–39}, particularly AD⁴⁰.

Materials and Methods

In silico studies. The impact of the A2V mutation on the structural features of the A β 1-6 peptide was investigated using classical molecular dynamics (MD) simulations with an all-atom approach using the AMBER ff99SB-ILDN force field⁴¹. The solvent environment was explicitly simulated using the Tip3p water model and applying three-dimensional periodic boundary conditions. A 1.0 nm cutoff for the direct calculation of non-bonded interactions was applied, and long-range electrostatics were treated with the particle-mesh Ewald approach. The systems were prepared by dispersing the A β 1-6_{WT} and A β 1-6_{A2V} peptides in a cubic box of side 5.0 nm, filled with water molecules, and were initially relaxed through energy minimization in order to avoid




Figure 7. Effects of TAT(D) on APP processing (A–D) and binding of peptides to amyloid deposits (E–H). Densitometric quantification of APP C-terminal fragments revealed an increase in the C99:C83 ratio in mice treated with A β 1-6_{A2V}TAT(D) every 7 days for 5 months (B,D), while no differences in C99:C83 ratio were observed at the beginning of the treatment (A,C). Statistical analysis was performed using a Student's t-test and differences were considered significant if $p < 0.05$. Immunohistochemistry with biotinylated peptides, original magnification 20 \times . Amyloid plaque immunohistochemistry in brain sections of CRND8 transgenic mice. **E** and **F** show transgenic mouse brain stained with Biot-A β 1-6_{WT}TAT(D) and Biot-A β 1-6_{A2V}TAT(D) respectively. **(G)**: transgenic mouse brain stained with Biot-TAT(D). **(H)**: transgenic mouse brain stained with Biot-A β 1-6_{A2V}(D). Arrow indicates a plaque that is not stained by Biot-A β 1-6_{A2V}. No immunoreactivity was detected in control non-transgenic mice slides co-incubated with Biot-D peptides (data not shown).

nonphysical contact between the solute and solvent molecules, then equilibrated with a 5 ns MD simulation at constant ambient pressure and temperature (300 K). The production runs were then extended for 1.5 μ s each. Covalent bonds involving hydrogen were constrained by applying the LINCS algorithm, allowing a simulation timestep of 2 fs⁴². Temperature was controlled by applying the Bussi-Donadio-Parrinello thermostat, while pressure was controlled with an isotropic Parrinello-Rahman barostat⁴³. All simulations were carried out using GROMACS 4.6.5⁴².

In vitro studies. Peptide synthesis. All synthetic peptides were prepared as previously described⁷ via solid-phase Fmoc chemistry on an Applied Biosystems 433 A peptide synthesizer, characterized by matrix-assisted laser desorption/ionization mass spectrometry (MALDI). Their purity was always above 95% (See Supplementary Information for details).

Polarized light, Electron Microscopy (EM). A β 1-42_{WT}, A β 1-6_{A2V}TAT(D) were dissolved in 10 mM NaOH and then diluted in an equal volume of 100 mM Tris-HCl, pH 7.0, to final concentrations (0.250 mM). In studies with peptide mixtures [A β 1-42_{WT} : A β 1-6_{A2V}TAT(D)], peptide solutions were prepared as described above at a final concentration of 0.250 mM at either 1:1 or 1:4 molar ratios. The samples were incubated at 37°C, and the tinctorial and ultrastructural properties of the peptide assemblies were determined at various intervals, ranging from 1 h to 20 days, as previously described⁷. The experiments were repeated five times.

Atomic Force Microscopy (AFM). A β 1-42_{WT} oligomers were formed following incubation of A β 1-42_{WT} at a final concentration of 100 μ M in phosphate buffer 50 mM, pH 7.4 at 4°C for 24 h, alone or in presence of A β 1-6_{A2V}TAT(D), at 1:4 molar ratio. Sample solutions were diluted to a final concentration of 10 μ M of A β 1-42_{WT} with phosphate buffer and 50 μ l of each solution was immediately added onto freshly cleaved mica at room




Figure 8. Serum levels of IgG against A β peptides after chronic treatment with A β 1-6_{A2V}TAT(D). To verify whether A β 1-6_{A2V}TAT(D) administration once a week for 5 months was associated with an immune response, we collected blood from mice before (T0) and at the end of the treatment (T2). Sera from saline (n = 8) and A β 1-6_{A2V}TAT(D) (n = 9) treated mice were tested induplicate using ELISA for the presence of IgG against A β 1-6_{A2V}TAT(D) (A), the full-length A β 1-42 (B), A β 1-6_{A2V} (C) and TAT(D) (D). Data are displayed both as the median (range) of each group and as individual values and represent optical density (O.D.) at 450 nm.

temperature for 2 minutes. Samples were washed and dried under gentle nitrogen flow. AFM analyses were carried out on a Multimode AFM with a Nanoscope V system (Veeco/Digital Instruments). AFM images were analysed using the Scanning Probe Image Processor data analysis package. All the topographic patterns and SPIP characterization were verified via additional measurements on a minimum of five different, well separated areas.

Binding of Biot-A β 1-6_{WT/A2V}TAT(D) to amyloid. It was tested on brain sections of transgenic and control mice of CRND8 strain⁴⁴. To unequivocally identify the fragment(s) of the peptide responsible for binding to plaques we used three separate segments: Biot-A β 1-6_{WT}(D), Biot-A β 1-6_{A2V}(D) and Biot-TAT(D). Seven-micrometre thick brain sections fixed in Carnoy and embedded in paraffin were used for staining. The immunoreaction was revealed by incubation with the avidin-biotin complex (Vectastatin ABC Kit, Vector Laboratories) and diaminobenzidine (DAB) as the substrate for horseradish peroxidase.

Cell models. Toxicity studies with A β 1-6_{WT}(D), A β 1-6_{A2V}(D) or A β 1-6_{A2V}TAT(D) and the short peptides' ability to inhibit the toxicity induced by A β 1-42_{WT} in SH-SY5Y cell cultures were analyzed following previously described protocols⁷. Each experiment was performed in triplicate; the data provided were obtained as the mean of three independent assays.

In vivo studies. **Animals.** Animal care and experimental procedures were conducted in accordance with European Union (2010/63/EU) and Italian (D. Lgs. 26/2014) legislations and followed the applicable rules and guidelines of the Animal care surveillance Committee of the INCB. All the experiments involving animals were approved by the Animal care surveillance Committee of the INCB and by the Italian Ministry of Health. All animals were sacrificed by cervical dislocation under deep anesthesia (telazol 20 mg/kg and medetomidine 1,5 mg/kg i.p.).

In vivo assessment of translocation across BBB. APP23 mice (Harlan, Correzzana, Italy) were treated by intraperitoneal injection with A β 1-6_{A2V}TAT(D) (10 mg/kg) or vehicle (saline solution) and sacrificed 1 h or 24 h after the last treatment. A β 1-6_{A2V}TAT(D) was quantified in mouse brain using HPLC-MS/MS⁴⁵. The stability of A β 1-6_{A2V}TAT(D) to protease digestion was also investigated by MALDI TOF MS (See Supplementary Information for details).

In vivo anti-amyloidogenic effects of A β 1-6_{A2V}TAT(D) in the huAPP^{Swe}/moAPP^{0/0} mouse model. Transgenic APP23 mice expressing the Swedish double mutation in the human APP gene⁴⁶ and knock-out for endogenous APP (huAPP^{Swe}/moAPP^{0/0}) were generated in our lab by crossing APP23 mice with APP^{0/0} animals. Mice (n = 6) were treated intraperitoneally (i.p.) every day for 21 days with A β 1-6_{A2V}TAT(D) (10 mg/kg) or saline solution and culled 24 h after the last treatment.

In vivo anti-amyloidogenic effects of A β 1-6_{A2V}TAT(D) in the APP^{Swe}/PS1^{dE9} mouse model. Heterozygous four-month-old female APP^{Swe}/PS1^{dE9} transgenic mice were used in this study. These mice express human APP carrying the Swedish mutation together with human presenilin 1 (PS1) carrying the pathogenic dE9 mutation⁴⁷. Animals were divided in 2 experimental groups (n = 10 each), treated i.p. once a week with saline solution or A β 1-6_{A2V}TAT(D) and culled 2.5 (intermediate time) and 5 months (final time) after treatment. In both mouse transgenic lines, the brain was removed and dissected into 2 hemibrains by midsagittal dissection. One half was immediately stored at 80 °C for biochemical assays, the other immediately immersed in formalin (10%) overnight for immunohistochemical studies.

Behavioral tests. The Novel Object Recognition test (NOR) was used to examine the cognitive performance of animal models involved in preclinical studies, following well consolidated protocols⁴⁸. The results of the NOR were expressed by using:

- Discrimination index (time exploring novel object - time exploring familiar object)/(time exploring novel object + time exploring familiar object).
- Recognition index (RI): time exploring novel object/(time exploring novel object + time exploring familiar object) %.

Biochemical studies. The left hemisphere of each brain was homogenized in 7 volumes of 10 mM Tris-HCl, pH 7.4, added with cOmplete Mini Protease Inhibitors cocktail (Roche), sonicated for 1 min using an ultrasonic homogenizer (SONOPULS) and centrifuged at 100,000 xg for 1 h at 4 °C. The supernatant was saved as the soluble fraction; the pellet was extracted in 70% formic acid and neutralized with 20 volumes of 1 M Tris (insoluble fraction).

A β 40, A β 42 and aggregated A β were measured in both soluble and insoluble fractions by ELISA (Invitrogen). Each experiment was performed in triplicate. The analysis of APP processing followed the protocol described above. After centrifugation, the supernatant was collected as the SDS-soluble fraction, which was analyzed by western blot with the A8717 antibody (Sigma). Signal intensity of the bands was measured by Quantity One (BioRad).

Neuropathological studies. Coronal slices of the right hemibrain were embedded in paraffin and cut (7 μ m); sections were de-waxed in xylene and hydrated through serial alcohols to water. After formic acid (80%) pre-treatment, sections were incubated overnight with anti-A β antibody (4G8, 1:4000; Covance). The primary antibody signal was detected with a biotinylated secondary antibody followed by horseradish streptavidin peroxidase and visualized with DAB. Amyloid deposition was quantified in mouse brain using A β immunostaining (4G8) and the staining intensity was evaluated semiquantitatively using a scale range from 0 to 5 by light microscopy. The assessment was conducted in two adjacent sections of the same brain area⁴⁹. A parallel quantification of the A β plaque load was performed using image analysis software (NIS-elements-Nikon)^{50–52}.

Measurement of serum antibodies against A β peptides. Sera were collected from mice before (T0) and at the end of the treatment (5 months), and tested using ELISA for the presence of IgG against A β 1-6_{A2V}TAT(D), the full-length A β 1-42, A β 1-6_{A2V}(D) and TAT(D) following previously described protocols for antigen-specific mouse IgG detection⁵³, except blocking buffer that was PBS 3% milk. Anti-A β 1-42 IgG antibodies from 6E10 IgG clone (Covance), and sera from mice immunized with A β 1-6_{A2V}TAT(D) or with A β 1-6_{A2V} emulsified in Complete Freund's adjuvant were used as positive controls.

Statistical analysis. Mann Withney U-test was used to compare data obtained by NOR test (Discrimination Index, Preference Index, Recognition Index). Comparison of cell viability after administration of A β 1-42, alone or together with A β 1-6_{A2V}TAT(D) or A β 1-6_{WT}TAT(D), was performed by Student t-test. Student t-test was also used to compare (i) amyloid burden in immunohistochemical studies, (ii) A β 40, A β 42 and aggregated A β levels obtained by ELISA tests, and (iii) relative amounts of APP C-terminal fragments after Western Blot quantification. Two tailed P value equal or less than 0.05 was considered statistically significant. All calculations were performed using GraphPad Prism 5.

References

1. Duyckaerts, C., Delatour, B. & Potier, M. C. Classification and basic pathology of Alzheimer disease. *Acta Neuropathol* **118**, 5–36, doi: 10.1007/s00401-009-0532-1 (2009).
2. Hyman, B. T. *et al.* National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement* **8**, 1–13, doi: 10.1016/j.jalz.2011.10.007 (2012).
3. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353–356, doi: 10.1126/science.1072994 (2002).
4. Shankar, G. M. *et al.* Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* **14**, 837–842, doi: 10.1038/nm1782 (2008).
5. Querfurth, H. W. & LaFerla, F. M. Alzheimer's disease. *N Engl J Med* **362**, 329–344, doi: 10.1056/NEJMra0909142 (2010).

6. Chow, V. W., Mattson, M. P., Wong, P. C. & Gleichmann, M. An overview of APP processing enzymes and products. *Neuromolecular Med* **12**, 1–12, doi: 10.1007/s12017-009-8104-z (2010).
7. Di Fede, G. *et al.* A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. *Science* **323**, 1473–1477, doi: 10.1126/science.1168979 (2009).
8. Di Fede, G. *et al.* Good gene, bad gene: new APP variant may be both. *Prog Neurobiol* **99**, 281–292, doi: 10.1016/j.pneurobio.2012.06.004 (2012).
9. Diomedea, L. *et al.* Expression of A2V-mutated A β in *Caenorhabditis elegans* results in oligomer formation and toxicity. *Neurobiol Dis* **62**, 521–532, doi: 10.1016/j.nbd.2013.10.024 (2014).
10. Messa, M. *et al.* The peculiar role of the A2V mutation in amyloid- β (A β) 1–42 molecular assembly. *J Biol Chem* **289**, 24143–24152, doi: 10.1074/jbc.M114.576256 (2014).
11. Chauhan, A., Tikoo, A., Kapur, A. K. & Singh, M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. *J Control Release* **117**, 148–162, doi: 10.1016/j.jconrel.2006.10.031 (2007).
12. Borsello, T. *et al.* A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. *Nat Med* **9**, 1180–1186, doi: 10.1038/nm911 (2003).
13. Colombo, A. *et al.* The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability. *Cell Death Differ* **14**, 1845–1848, doi: 10.1038/sj.cdd.4402202 (2007).
14. Zhu, Y., Bu, Q., Liu, X., Hu, W. & Wang, Y. Neuroprotective effect of TAT-14-3-3 ϵ fusion protein against cerebral ischemia/reperfusion injury in rats. *PLoS One* **9**, e93334, doi: 10.1371/journal.pone.0093334 (2014).
15. Daura, X. *et al.* Peptide folding: when simulation meets experiment. *Angew. Chem. Int. Ed. Engl.* **38**, 236–240 (1999).
16. Reitz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. *Nat Rev Neurol* **7**, 137–152, doi: 10.1038/nrneurol.2011.2 (2011).
17. Galimberti, D. & Scarpini, E. Alzheimer's disease: from pathogenesis to disease-modifying approaches. *CNS Neurol Disord Drug Targets* **10**, 163–174 (2011).
18. Rampa, A., Gobbi, S., Belluti, F. & Bisi, A. Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment? *Curr Top Med Chem* **13**, 1879–1904 (2013).
19. Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C. L. & Beyreuther, K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. *J Mol Biol* **228**, 460–473 (1992).
20. Franco, R. & Cedazo-Minguez, A. Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? *Front Pharmacol* **5**, 146, doi: 10.3389/fphar.2014.00146 (2014).
21. Schneider, L. S. *et al.* Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. *J Intern Med* **275**, 251–283, doi: 10.1111/joim.12191 (2014).
22. Soto, C. & Estrada, L. Amyloid inhibitors and beta-sheet breakers. *Subcell Biochem* **38**, 351–364 (2005).
23. Wu, Y. *et al.* Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models. *Sci Rep* **5**, 15032, doi: 10.1038/srep15032 (2015).
24. Parthasarathy, V. *et al.* A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1 Δ E9 mouse model of Alzheimer's disease. *PLoS One* **8**, e54769, doi: 10.1371/journal.pone.0054769 (2013).
25. Taylor, M. *et al.* Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. *Biochemistry* **49**, 3261–3272, doi: 10.1021/bi100144m (2010).
26. Giunta, B. *et al.* HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. *Int J Clin Exp Pathol* **2**, 433–443 (2009).
27. Rempel, H. C. & Pulliam, L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. *AIDS* **19**, 127–135 (2005).
28. Kim, J., Yoon, J. H. & Kim, Y. S. HIV-1 Tat interacts with and regulates the localization and processing of amyloid precursor protein. *PLoS One* **8**, e77972, doi: 10.1371/journal.pone.0077972 (2013).
29. Jonsson, T. *et al.* A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature* **488**, 96–99, doi: 10.1038/nature11283 (2012).
30. Kero, M. *et al.* Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. *Neurobiol Aging* **34**, 1518.e1511–1513, doi: 10.1016/j.neurobiolaging.2012.09.017 (2013).
31. Hashimoto, Y. & Matsuo, M. A mutation protective against Alzheimer's disease renders amyloid β precursor protein incapable of mediating neurotoxicity. *J Neurochem* **130**, 291–300, doi: 10.1111/jnc.12717 (2014).
32. Maloney, J. A. *et al.* Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. *J Biol Chem* **289**, 30990–31000, doi: 10.1074/jbc.M114.589069 (2014).
33. Benilova, I. *et al.* The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid- β (A β) aggregation. *J Biol Chem* **289**, 30977–30989, doi: 10.1074/jbc.M114.599027 (2014).
34. Liu, Y. W. *et al.* Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. *Neurobiol Aging* **35**, 935.e911–932, doi: 10.1016/j.neurobiolaging.2013.09.023 (2014).
35. Wang, L. S. *et al.* Rarity of the Alzheimer disease-protective APP A673T variant in the United States. *JAMA Neurol* **72**, 209–216, doi: 10.1001/jamaneurol.2014.2157 (2015).
36. Khafagy, e.-S. & Morishita, M. Oral biodrug delivery using cell-penetrating peptide. *Adv Drug Deliv Rev* **64**, 531–539, doi: 10.1016/j.addr.2011.12.014 (2012).
37. Kang, W. H., Simon, M. J., Gao, S., Banta, S. & Morrison, B. Attenuation of astrocyte activation by TAT-mediated delivery of a peptide JNK inhibitor. *J Neurotrauma* **28**, 1219–1228, doi: 10.1089/neu.2011.1879 (2011).
38. Deng, B. *et al.* Targeted delivery of neurogenin-2 protein in the treatment for cerebral ischemia-reperfusion injury. *Biomaterials* **34**, 8786–8797, doi: 10.1016/j.biomaterials.2013.07.076 (2013).
39. Arribat, Y. *et al.* Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease. *Acta Neuropathol Commun* **2**, 86, doi: 10.1186/s40478-014-0086-x (2014).
40. Lou, G. *et al.* Intranasal administration of TAT-haFGF_(14–154) attenuates disease progression in a mouse model of Alzheimer's disease. *Neuroscience* **223**, 225–237, doi: 10.1016/j.neuroscience.2012.08.003 (2012).
41. Lindorff-Larsen, K. *et al.* Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins* **78**, 1950–1958, doi: 10.1002/prot.22711 (2010).
42. Lindahl, E., Hess, B. & van der Spoel, D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. *J Mol Model* **7**, 306–317 (2001).
43. Parrinello, M. & Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. *J Appl Phys* **52**, 7182–7190 (1981).
44. Chishti, M. A. *et al.* Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. *J Biol Chem* **276**, 21562–21570, doi: 10.1074/jbc.M100710200 (2001).
45. Davoli, E. *et al.* Determination of tissue levels of a neuroprotectant drug: the cell permeable JNK inhibitor peptide. *J Pharmacol Toxicol Methods* **70**, 55–61, doi: 10.1016/j.vascn.2014.04.001 (2014).
46. Sturchler-Pierrat, C. & Staufenbiel, M. Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. *Ann N Y Acad Sci* **920**, 134–139 (2000).
47. Puli, L. *et al.* Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. *J Neuroinflammation* **9**, 105, doi: 10.1186/1742-2094-9-105 (2012).

48. Antunes, M. & Biala, G. The novel object recognition memory: neurobiology, test procedure, and its modifications. *Cogn Process* **13**, 93–110, doi: 10.1007/s10339-011-0430-z (2012).
49. Capetillo-Zarate, E. *et al.* Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. *Brain* **129**, 2992–3005, doi: 10.1093/brain/awl176 (2006).
50. Garcia-Alloza, M. *et al.* Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. *Neurobiol Dis* **24**, 516–524, doi: 10.1016/j.nbd.2006.08.017 (2006).
51. DaRocha-Souto, B. *et al.* Brain oligomeric β -amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. *J Neuropathol Exp Neurol* **70**, 360–376, doi: 10.1097/NEN.0b013e318217a118 (2011).
52. Samaroo, H. D. *et al.* High throughput object-based image analysis of β -amyloid plaques in human and transgenic mouse brain. *J Neurosci Methods* **204**, 179–188, doi: 10.1016/j.jneumeth.2011.10.003 (2012).
53. Costanza, M., Musio, S., Abou-Hamdan, M., Binart, N. & Pedotti, R. Prolactin is not required for the development of severe chronic experimental autoimmune encephalomyelitis. *J Immunol* **191**, 2082–2088, doi: 10.4049/jimmunol.1301128 (2013).

Acknowledgements

This study was supported by the Telethon Foundation (Project GGP10120), the Italian Ministry of Health RF-2009-1473239 and Banca Intesa Sanpaolo 2014-2015 Grant. We thank Flamma srl (Bergamo, Italy) for the kind gift of FMOC peptides.

Author Contributions

G.D.F. was responsible for the conception of hypotheses, design of study and analysis of results. M.Salv. performed *in silico* studies. M.C. was involved in *in vitro* studies on cell lines and *in vivo* biochemical studies. M.M. and L.P. performed ultrastructural studies. F.M. and E.M. were responsible for behavioural assessment in animal models. E.M. and G.G. were involved in neuropathologic studies. L.C. was involved in AFM studies and analysis of binding of biotinylated peptides to amyloid. M.R., I.C. and T.V. performed treatments of animals. M.C. and R.P. performed immunological studies. A.C. and L.C. were responsible for peptide synthesis and purification. A.R. and L.C. were involved in HPLC-MS/MS analysis and MALDI TOF MS studies for the measurement of BBB cross, serum stability and brain levels of peptides. F.T. and M.S. were responsible for scientific input, coordination of the experimental plan and analysis of the results.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: G.D.F., M.M. and F.T. have a patent 0001383392 issued and a patent 08838209.8 pending, both related to this work.

How to cite this article: Di Fede, G. *et al.* Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid- β . *Sci. Rep.* **6**, 20949; doi: 10.1038/srep20949 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>